Main Uses and Benefits of Ацилакт (Acilact)

Ацилакт (Acilact) is a probiotic containing the beneficial bacterium Lactobacillus acidophilus, which may assist with managing symptoms related to systemic imbalance by helping to support the natural balance of microorganisms. The general category of products containing Lactobacillus is commonly used across conditions presenting with acute episodes where microbial disruption has occurred. For example, the product may be part of symptomatic management for situations involving digestive distress, symptoms related to a disturbed intestinal flora following antibiotic use, or symptoms that interfere with daily functioning linked to systemic or localized discomfort.

Quick Fact: Relief for Symptom Clusters

The use of probiotics is relevant in contexts involving inflammatory or irritative states and is commonly used in areas where short-term symptom management is appropriate. By contributing to a favorable microbiological environment, this product contributes to easing the overall symptom load associated with a disturbed environment. This is applied in addressing symptom clusters that may become intense or disruptive, and may help patients cope more steadily with symptom fluctuations. The use of probiotics is considered relevant for easing symptoms related to physical discomfort, such as those impacting the digestive system. This supportive approach helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. NIH NCCIH Overview on Probiotics

Who Can and Cannot Use Acilact (Ацилакт)—Official Regulatory Information

Eligibility for Acilact, a preparation containing Lactobacillus acidophilus, is determined by specific exclusions detailed in official regulatory documentation.

Contraindications and Restrictions

The medicine is contraindicated (must not be used) for certain populations and under specific clinical conditions:

• Hypersensitivity: Individuals with a known allergy or hypersensitivity to the active substance or any other component of the formulation are excluded from use.
• Candidiasis: The presence of vulvovaginal candidiasis (a yeast/fungal infection) constitutes a condition-based contraindication.
• Age Restriction: The tablet dosage form is explicitly contraindicated in childhood. Eligibility for the tablet form is restricted to adults.

Population Status	Regulatory Rule
Pregnancy and Lactation	Use is allowed (not contraindicated)
Children	Tablet form is Contraindicated
Adults	Use is generally allowed if no contraindications exist

These restrictions define the official eligibility profile and must be strictly followed.

The interaction profile for Ацилакт (Lactobacillus acidophilus) is defined by its nature as a viable microbiological agent, leading to pharmacodynamic conflicts rather than metabolic interactions.

The most significant documented interaction is a pharmacodynamic conflict with antibacterial agents (antibiotics). Official regulatory documents state that co-administration may reduce the product's efficacy by deactivating the active ingredient, the viable bacterial culture. This documented interaction necessitates a mandatory timing constraint for administration. To minimize this effect, Ацилакт must be taken at least 2 hours before or after the administration of any antibacterial medicine, as specified in regulatory labeling.

Additionally, official product information includes specific interaction-related cautions regarding use in certain populations. The use of this live microbiological preparation in patients who are immunosuppressed or receiving immunosuppressive therapy is documented as a Moderate Potential Hazard requiring caution due to the nature of the live agent. Furthermore, regulatory sources note that the co-consumption of alcohol may pose an interaction risk. The official interaction profile does not include information on CYP enzyme- or transporter-mediated pharmacokinetic interactions.

Regulation of Local Microbial Balance

Acilact, which utilizes live Lactobacillus acidophilus strains, acts by directly colonizing mucosal surfaces, particularly the vagina and intestines. This action falls within the microbial ecology domain and primarily involves competitive exclusion of non-resident bacteria for nutrient and binding sites. It also includes the production and release of antimicrobial compounds. The resulting mechanistic consequence is the influence on the local microenvironment conditions.

---

Modulation of the Acid-Base Environment

A central mechanistic function is the metabolic production of lactic acid and other short-chain fatty acids (SCFAs) by the Lactobacillus strains. This process, relevant in the metabolic pathway domain, lowers the local pH. This predictable physiological adjustment establishes conditions that impede the growth rate of non-resident microbial populations that exhibit pH sensitivity.

---

Influence on Immune System Signaling

The components of Acilact engage mechanisms that modulate key signaling pathways associated with immune processes, operating within the receptor- or enzyme-mediated signaling domain localized to mucosal immunity. This includes influencing the functional status of immunocompetent cells and regulating the expression of specific mediators. The resulting system-level physiological consequence is a modulation of local immune cell responsiveness.

How to Use Ацилакт: Administration Guidelines

Administration of Ацилакт, which contains the active ingredient Lactobacillus acidophilus, is determined by its dosage form. Administration is defined by two routes: oral (for capsules, tablets, and powder) and intravaginal (for suppositories).

---

Administration Scope

Entity	Administration Guidelines
Route of Administration	Oral route; Intravaginal route.
Dosing Schedule	Doses are expressed in Colony Forming Units (CFU) per day. The intravaginal dose is typically one unit daily.
Preparation	Lyophilized powder must be mixed with liquid (e.g., water, juice) prior to ingestion.
Missed Dose Rule	Skip the missed dose if it is almost time for the next dose; do not double the dose to compensate.

---

Dosing Frequency and Procedural Instructions

The frequency and duration of use are structured to include both acute treatment and long-term maintenance. For the intravaginal form, the initial treatment is a time-bound course (e.g., typically a minimum of 12 days), followed by an optional intermittent maintenance schedule (e.g., 2 to 3 times per week). Oral forms are generally administered once daily or in divided doses.

Crucially, the oral dose may be taken with or without food, but administration must be separated from antibiotics by an interval of at least two hours to maintain the viability of the active culture. The intravaginal unit should be inserted deeply into the vagina, often at bedtime. Regarding age-specific rules, the intravaginal dosage form is restricted from use in premenarcheal girls.

Connection to the Overall Use Protocol

These instructions establish a structured protocol centered on route determination and precise timing. The protocol mandates specific preparation for the powder form and requires adherence to the standardized initial course duration before transitioning to any maintenance frequency. The rules also explicitly enforce procedural steps, such as the timing separation from antibiotics and the restriction for certain age groups.

Research Evidence / Overview of Studies

Phase 3 Trials: Joint Function and Pain

Studies have evaluated whether the drug is associated with changes in joint function and pain reduction in participants with chronic osteoarthritis.

• Study Design: The primary studies were double-blind, placebo-controlled trials over a 12-week period, involving over 800 participants diagnosed with chronic knee or hip osteoarthritis.
• Key Findings: Differences in the mean patient-reported pain scores (measured on the VAS scale) were observed between the active treatment group and the placebo group. The study recorded differences in Functional mobility scores (measured by the WOMAC index) between the groups at the final assessment point.
• Safety Profile: The safety and tolerability of the drug were assessed during the trials. Adverse events reported most frequently were classified as mild to moderate gastrointestinal disturbances. Participants with a history of liver disease were often excluded from the studies.

---

Mechanism of Action and Combined Therapy

Clinical trials explored the effect of the active ingredient, noting that some participants reported a change in symptoms.

• Combination Treatment: Research has also evaluated whether the combination demonstrates a different therapeutic effect compared to monotherapy. Research examined the association between the treatment and changes in severe joint pain.
• Bioavailability Research: Studies have examined whether taking the drug with food affects its absorption.

---

Patient Safety and Dosage

• Adherence and Dosing: Trial protocols defined the administration schedule used in the study.
• Long-term Data: Data on use extending beyond one year remains limited for this specific formulation.

Common questions about Ацилакт (FAQ)

Q: Why is Ацилакт specifically used for conditions involving the female reproductive system?

According to official product information, Ацилакт is used for the restoration of microflora balance. It is available in a vaginal suppository form for local administration, which is the basis for its application in conditions affecting the female reproductive system. Regulatory-cited uses include addressing issues associated with intestinal flora restoration and post-antibiotic vulvovaginal candidiasis.

---

Q: Can Ацилакт be taken at the same time as cold medicine?

The primary timing constraint noted in regulatory documents involves separation from antibacterial medicines (antibiotics). Official product information does not typically list specific interactions with common non-antibiotic cold remedies. Patients are advised to discuss the use of all non-prescription medicines with a healthcare professional.

---

Q: Are there any common foods or drinks that should be avoided when using Ацилакт?

Official regulatory information mentions that consumption of alcohol may pose an interaction risk with this product. Regarding food, the oral dosage form is described as being safe to take with or without food.

---

Q: Does Ацилакт help with overall digestion or just specific conditions?

The general purpose of the product is described as the restoration and maintenance of healthy bacteria in the body's microflora. Official documentation suggests its use for managing issues such as post-antibiotic diarrhea and supporting the balance of intestinal flora.

---

Q: Is it safe for older adults (seniors) to use Ацилакт?

Official regulatory information typically states that no specific information is available regarding the relationship of age to the effects of the active ingredient in geriatric patients (older adults). Official information does not provide specific guidance or restrictions for the geriatric population.

---

Q: Does Ацилакт interact with common pain relievers like paracetamol?

The most significant documented interaction is a required separation from antibacterial agents. Official product information does not generally specify interactions with common non-antibiotic pain relievers like paracetamol. Patients are advised to discuss the use of all prescription and non-prescription medicines with a healthcare professional.

---

Q: How long after finishing a course of antibiotics can I start taking Ацилакт?

Official labeling describes a timing constraint requiring separation from antibiotic administration by at least two hours when taken concurrently. Some regulatory guidance also notes that the product may be recommended to be continued for several days after the antibiotic treatment has finished to help restore microbial balance.

---

Q: Why is the dosage for children different from adults?

Official information states that the oral dosage and use protocol for children are subject to a doctor's determination. Furthermore, the tablet form is contraindicated in childhood in some regional documents, indicating different use restrictions based on age.

---

Q: Is it better to take Ацилакт in the morning or evening?

For oral dosage forms (capsules, tablets, or powder), official instructions state the medicine may be taken at any time, with or without food. However, the intravaginal dosage form (suppositories) is typically inserted at bedtime.

---

Q: Can Ацилакт be used long-term?

The usage protocol includes an initial course followed by an optional intermittent maintenance schedule. However, regulatory-cited research notes that formal data on use extending beyond one year remains limited for this specific formulation.

---

Q: Is it described as appropriate for people with lactose intolerance?

The active ingredient, Lactobacillus, is a type of bacteria that can produce lactase, the enzyme that digests lactose. Official product precautions include disclosing to a healthcare professional any known allergies, including those to milk or lactose products, due to the potential presence of inactive ingredients.

---

Q: Do the ingredients in Ацилакт contain gluten or common allergens?

Official precautions note the importance of discussing known allergies to foods, dyes, or preservatives with a healthcare professional. Information regarding allergens like gluten can generally be found by reviewing the label or package ingredients for non-prescription forms.

---

Q: Does official labeling mention any warnings about kidney or liver issues and Ацилакт use?

Regulatory-cited research notes that participants with a history of liver disease were often excluded from studies. Official labeling generally cautions about use in individuals with serious underlying conditions, which may include major organ impairment.

---

Q: Is the research evidence for Ацилакт considered strong or limited?

Regulatory-cited documents confirm the completion of Phase 3, double-blind, placebo-controlled trials for specific outcomes. At the same time, official information also points out that data on use extending beyond one year remains limited for this specific formulation.

---

Q: Is it described as being suitable for people with a weakened immune system?

Official regulatory safety information states that the product is contraindicated in patients with a severely weakened immune system or serious underlying conditions due to the rare risk of systemic infection. Regulatory documents note that the use of the product in immunocompromised individuals requires caution and supervision by a healthcare professional.

---

Q: Does official information clarify how many courses of Ацилакт can be taken in a year?

The administration protocol specifies an initial time-bound course, followed by an optional intermittent maintenance schedule. However, official regulatory documents do not typically specify an explicit maximum number of courses that can be taken within a year.

---

Q: How does the concentration of bacteria in Ацилакт compare to over-the-counter supplements?

Regulatory labeling requires listing the product's concentration in Colony Forming Units (CFUs) on the package. Official guidance suggests that the efficacy of probiotic strains is highly dependent on the dosage, and commercial products can vary widely in their viable bacteria content.

Storage and Handling Requirements

Acilact is a biological preparation requiring strict temperature and environmental control to maintain product stability and the viability of the active component, Lactobacillus acidophilus.

Storage Entity	Regulatory Requirement
Temperature Range	Mandatory storage between mathbf2 C and mathbf10 C (refrigeration).
Prohibited Conditions	The medicine must not be frozen.
Protection	Must be stored in a dry, dark place and protected from light.
Shelf Life	Documented shelf life is mathbf2 years when stored continuously under these required conditions.
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

As dictated by official labeling, any unused or expired Acilact medicinal product must be disposed of according to local requirements for pharmaceutical waste.